Platelet adhesion and aggregation interfaces

Platelet adhesion and aggregation interfaces represent the molecular contact points between platelets and the vascular wall or between individual platelets, which are essential for hemostasis and the pathogenesis of arterial thrombosis (StatPearls, NBK545271). Adhesion is the initial step, primarily mediated by the interaction between the platelet Glycoprotein Ib-IX-V complex and von Willebrand factor (vWF) immobilized on the exposed subendothelial matrix (NCBI, PMC3426372). This is followed by platelet activation and aggregation, where Integrin alpha-IIb beta-3 (GPIIb/IIIa) undergoes a conformational change to bind bivalent ligands like fibrinogen, effectively cross-linking platelets into a stable thrombus (UniProt, P08514). These interfaces are major therapeutic targets in cardiovascular diseases, including myocardial infarction and ischemic stroke, where pathological thrombus formation can lead to vessel occlusion. Pharmacological intervention includes direct inhibitors of these interfaces, such as GPIIb/IIIa antagonists (e.g., Abciximab) and vWF-targeting nanobodies (e.g., Caplacizumab), as well as indirect inhibitors like P2Y12 receptor antagonists that prevent the signaling required for interface activation (FDA, ReoPro Label). Monitoring of these interfaces is often performed using platelet function assays such as light transmission aggregometry or flow cytometry for activation markers like P-selectin (PubMed, 24037915). While highly effective in preventing thrombotic events, targeting these interfaces carries a significant risk of bleeding complications due to the impairment of normal hemostatic processes.

Other names

Platelet-vessel wall interactionsPlatelet-platelet interactionsThrombotic interfacesPlatelet surface receptorsPlatelet adhesion receptors

Inhibition of ligand binding to platelet surface receptors (e.g., fibrinogen to GPIIb/IIIa, vWF to GPIb) or inhibition of signaling pathways (e.g., P2Y12, COX-1) that lead to the activation of these interfaces.